Completed PHASE3 NCT00002070
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
Sponsor: Schering-Plough
Conditions
Cytomegalovirus Retinitis HIV Infections
Interventions
Ganciclovir Sargramostim
Updated 5 times since 2017 Last updated: Jun 23, 2005
This PHASE3 trial investigates Cytomegalovirus Retinitis and HIV Infections and is currently completed. Schering-Plough leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Schering-Plough
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Annandale, United States
- • Atlanta, United States
- • Chicago, United States
- • Dallas, United States
- • Houston, United States
- • Los Angeles, United States
- • New York, United States
- • Philadelphia, United States
- • San Francisco, United States
- • Sherman Oaks, United States